RxDoctor Payments DataLook up a doctor →

Robert Silzer, MD

Neurology · Little Rock, ARNPI 1881626257

Payments from drug & device makers

$13,759in general payments, 2019–2025

Across 651 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Amgen$838
  • EMD Serono, Inc.$831
  • Novartis$810
  • TG Therapeutics, Inc.$768
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$13,67899%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,759 in reported general payments places this provider in the 70th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$81,738
Medicare patients
368
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4627$379,863
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5037$349,443
OctagamImmun Globg(Igg)/Malt/Iga Ov5032$260,029
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$191,923
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5011$138,835
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$126,716
Nurtec OdtRimegepant Sulfate21$40,055
UbrelvyUbrogepant32$31,898
Aimovig AutoinjectorErenumab-Aooe31$24,798
Emgality PenGalcanezumab-Gnlm23$20,764
Gabapentin179$4,389
Pyridostigmine Bromide31$3,057
Carbidopa-LevodopaCarbidopa/Levodopa85$3,034
Duloxetine Hcl97$2,545
Ropinirole Hcl81$1,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kedrion Biopharma, Inc.Gammaked$421$379,86327 claims
CSL BehringPrivigen$355$349,44337 claims
PfizerOctagam, Nurtec Odt$381$300,08453 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$112$191,92314 claims
Bio Products Laboratory USA, Inc.Gammaplex$95$138,83511 claims
Grifols USA, LLCGamunex-C$28$126,71613 claims
AbbVieUbrelvy$2,458$31,89832 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$347$3,05731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 93 neurology providers in Arkansas.

Other neurology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →